Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of$ 0.22. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -9.09%. A quarter ago, it was expected that this biotechnology company would post a loss of$ 0.18 per share when it actually produced a loss of $0.24, delivering a surprise of -33.33%. Over the last four quarters, the ...